Vicore Pharma cancels the AGM on May 8, 2018

Vicore Pharma Holding (publ) (ticker: VICO) today announces that the company has decided to cancel the Annual General Meeting scheduled for May 8, 2018. The reason for canceling the meeting is that the company has noted that the notice to attend the Annual General Meeting was published in Post- och Inrikes Tidningar one day late and that therefore there would have existed reason for disputing the resolutions passed at the Annual General Meeting on May 8, 2018. The company will determine a new date for the Annual General Meeting shortly and in connection thereto publish renewed summon documents.

For further information, please contact:

Per Jansson, CEO
Tel: +46 70 917 47 46
per.jansson@vicorepharma.com 

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14:45 CET on May 7, 2018.

About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see  www.vicorepharma.com

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links